SciSparc unit NeuroThera pursues FDA orphan drug designation for adult Tourette
NeuroThera Labs, a SciSparc subsidiary, is pursuing FDA orphan drug designation for an adult Tourette Syndrome treatment and has engaged RK Strategies for government and public affairs support.
NeuroThera says the strategic engagement is intended to strengthen its U.S. market position, raise visibility with key U.S. federal stakeholders and reinforce the clinical and public-health importance of advancing new treatment options for adult Tourette syndrome.